September 2026 Research Update

This month added a clearer picture that delivering idursulfase beta directly into the fluid around the brain can lower a key storage marker in that fluid for a sustained period, and that timing may matter for development. The evidence comes from routine-care follow-up without a comparison group, so it cannot prove how much of the developmental change is due to treatment, but it does describe a consistent biomarker drop and a noticeable difference by age at start. Safety findings also help define what problems can occur with this approach in real-world use. [1]

In 37 Japanese male patients treated between 2021 and 2024, heparan sulfate in spinal fluid (a chemical that builds up in Hunter syndrome) fell by week 24 and stayed reduced through week 100. Children who began treatment at 3 years old or younger had developmental progress that stayed closer to what is seen in healthy children, while those who started later did not show the same pattern in this interim report. The study also reported that no anti-IDS antibodies were detected in spinal fluid during follow-up, which may matter because antibodies can sometimes interfere with enzyme treatments. [1]

Side effects were common, and some were linked to the implanted device and procedure needed to deliver the medicine. Among the safety population of 36 patients, adverse events were reported in 20 people, and serious procedure-related problems, including bacterial meningitis and a device-related infection, were reported in 2 people; fever was one of the more frequent treatment-related events. No deaths or anaphylaxis were reported in this interim analysis. [1]

For families focused on brain and developmental outcomes in neuronopathic Hunter syndrome, these results mainly add early real-world evidence that this brain-directed treatment can durably lower a spinal-fluid marker, and that earlier start was linked with more typical developmental progress in this group. Because there was no untreated comparison group and this was an interim look, it does not settle how much benefit any one child can expect, but it sharpens the questions researchers and families care about: how strongly marker reductions connect to day-to-day development, and how much timing changes the trajectory. Right now, the most immediate value is a better description of what has been observed so far in routine care, including the kinds of device- and infection-related complications that can happen with this delivery method. [1]

This month strengthened the view that Hunter syndrome does not follow one single cognitive pattern, and that the type of IDS gene change can help explain why some children decline earlier than others. The study followed patients over time, which helps show direction of change rather than a single snapshot. It also highlights that, within neuronopathic disease, some genetic changes track with especially rapid decline. [2]

In a Dutch nationwide cohort of 23 males, non-neuronopathic patients tended to have normal or only mildly affected cognition over time, while neuronopathic patients showed cognitive decline with age. In the neuronopathic group, IQ values dropped below 70 by a median age of 4 years. Deletions in the IDS gene showed the earliest and fastest decline, while other variant types (missense, nonsense, frameshift) had more variable paths. [2]

The authors noted that combining results across different age-appropriate cognitive tests can add variability, and that classifying patients only as neuronopathic or non-neuronopathic may miss intermediate patterns. Even with these limits, the work adds practical detail for understanding expected cognitive change over time, especially when an IDS deletion is present. [2]

For patients and caregivers, this study mainly helps with understanding prognosis and planning for support needs by describing how cognition can change over childhood in different forms of Hunter syndrome. It may matter now for setting expectations around monitoring and day-to-day supports, but it does not test a treatment or predict an individual child with certainty. What remains uncertain is how well these group-level trajectories apply to children with mixed features, or to those receiving newer brain-directed treatments, since this work focused on natural cognitive trajectories and genotype patterns. [2]

This month included a step toward more consistent testing for immune reactions to idursulfase beta, focused specifically on IgE antibodies (the antibody type often linked to allergic reactions). The work did not assess patient outcomes, but it reported that the test itself performed reliably by common lab standards. This kind of tool matters because it can make future safety and immune-response research easier to compare across settings. [3]

Researchers developed an ELISA blood test to detect anti-idursulfase beta IgE antibodies and reported analytical checks such as sensitivity, specificity, precision, stability, and ability to work even when drug is present in the sample. They also created a linked IgG-IgE positive control material to help the test run consistently. The study concluded the assay was suitable for characterizing the IgE antibody type against idursulfase beta in human serum samples. [3]

For families, this is mainly early laboratory groundwork rather than something that changes care by itself. It helps clarify that researchers now have a validated way to look for a specific kind of allergy-related antibody response to idursulfase beta, which could matter later if studies link these antibodies to infusion reactions or other safety questions. What remains unknown from this report is how often these IgE antibodies occur in treated patients and what they mean for symptoms, since patient results were not reported here. [3]